New study validates the prognostic value of the HER2DX test in HER2-positive breast cancer
Researchers from the Clínic Barcelona Comprehensive Cancer Center—driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona—toget1
Researchers from the Clínic Barcelona Comprehensive Cancer Center—driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona—toget1
The Clínic Barcelona Comprehensive Cancer Center (4CB), driven by Hospital Clínic, IDIBAPS, and the University of Barcelona, strengthens its internat1
Hospital Clínic-IDIBAPS is the only hospital in Europe to have fully developed two academic CAR T-cell therapies that have been approved by a regulat1
“I didn’t know what my present or my future would be like. I was very scared”, recalls Olga Federico of the time when she was diagnosed with breast1
The creation of the Clínic Barcelona Comprehensive Cancer Center represents a step forward in the integration of care, clinical research, translation1
Researchers at IDIBAPS- Hospital Clínic have developed and validated a new CAR-T therapy called ARI0003 at a preclinical level. The new therapy combi1
Researchers from Hospital Clínic-IDIBAPS have led a study that has found a correlation between anti-tumour immunological activity and longevity in br1
The promoters donated all the proceeds from the concert held on 3 October 2024 to commemorate the 25th anniversary of the death of the Catalan music1
The Campus Clínic Sponsorship Area presents the results of the 2024 “Let’s Turn the Page! Books against Cancer” project, which turns reading into an1
Chemotherapy and radiotherapy treatments have been associated with heart problems such as heart attacks and heart failure. To assess the benefits of1